Ann: $6.6 million Placement to advance clinical trial pipeline, page-77

https://penntoday.upenn.edu/news/dual-target-car-t-cell-therapy-slows-growth-aggressive-brain-cancer

Pity our CLTX trial in GBM had to be put on hold!

Our CDH17 trial should trump the results of the 2nd-gen CAR-T technology of Satri-cel. Its a shame that the results garnering just a couple of extra months for patients over SOC or TPC can lay claim to being the first breakthrough in solid tumours in a CAR-T Phase 2 trial.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext

Headlines such as: "Immunotherapy trial helps cancer patients with tumours live 40% longer. Experts praise groundbreaking results from therapy using genetically modified Car T-cells."

Eventhough they get to lay down fame at this juncture in the solid tumour space, it will attract attention to the field, and hopefully, our 3rd-gen technology is proving to be miles ahead. At the end of the day, that's what will matter here!